Ascletis Pharma Inc. (HKG:1672)
Hong Kong
· Delayed Price · Currency is HKD 16.60
-0.08 (-0.48%)
Apr 29, 2026, 3:13 PM HKT
Ascletis Pharma Employees
Ascletis Pharma had 231 employees as of December 31, 2024. The number of employees increased by 12 or 5.48% compared to the previous year.
Employees
231
Change (1Y)
12
Growth (1Y)
5.48%
Revenue / Employee
10.85K HKD
Profits / Employee
-1.93M HKD
Market Cap
17.70B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,784 |
| Keymed Biosciences | 1,625 |
| Ascentage Pharma Group International | 767 |
| Duality Biotherapeutics | 231 |
| CStone Pharmaceuticals | 136 |
| InnoCare Pharma | 1,176 |
| Genscript Biotech | 6,165 |
| CARsgen Therapeutics Holdings | 355 |
Ascletis Pharma News
- 2 days ago - Ascletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetes - PRNewsWire
- 21 days ago - Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development - PRNewsWire
- 7 weeks ago - Ascletis Announces Positive Topline Results from U.S. Phase II, 24-Week Study for Its Ultra-Long-Acting Subcutaneous Depot Formulations of Small Molecule GLP-1R Agonist ASC30 for Obesity - PRNewsWire
- 2 months ago - Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development - PRNewsWire
- 3 months ago - Ascletis Announces First Participants Dosed in a 13-week U.S. Phase II Study with ASC30, an Oral Small Molecule GLP-1R Agonist for the Treatment of Diabetes - PRNewsWire
- 3 months ago - Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development - PRNewsWire
- 4 months ago - Ascletis Announces U.S. FDA IND Clearance for 13-Week Phase II Study of Its Oral Small Molecule GLP-1, ASC30, in Participants with Diabetes - PRNewsWire
- 4 months ago - Ascletis Announces Positive Topline Results from U.S. Phase I Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor - PRNewsWire